Shareholder Updates

Viewing stories tagged shareholder

18 October 2017

Shareholder Update October 2017

In this issue: 

>> DEP® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel® BV phase 3 results

>> Update on other internal DEP® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

 

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

19 January 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)


13 April 2016

Shareholder Update April 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar® for 2,4-D

> DEPTM cabazitaxel shows superior performance

> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEPTM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand

> MOU for VivaGel® condom in China

> Half-year financial results

> Bio-Europe® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

 

29 October 2015

Shareholder Update October 2015

In this Issue:

› EU marketing approval granted for VivaGel® BV
› Multi-product DEP® license with AstraZeneca
› VivaGel® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

23 March 2015

Shareholder Update March 2015

In this Issue:

› Phase 1 DEP™ docetaxel clinical trial update
› DEP™ docetaxel in the news
› Partner news
› Starpharma targeting key growth areas in Oncology
› Bacterial vaginosis: Prevention of recurrence/Symptomatic relief
› VivaGel® condom
› Corporate news
› Starpharma half yearly financial results

 

Download: Shareholder Update March 2015 (pdf file, 1MB)

7 October 2014

Shareholder Update October 2014

In this Issue:

› Encouraging clinical data for DEP™ docetaxel

› VivaGel® condom approved for sale in Australia – Launch imminent

› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief

› Starpharma completes $18M Placement; launches $5M SPP

› Dendrimer-enhanced agrochemicals

› Full Year 2014 annual financial results

 

Download: Shareholder Update October 2014 (pdf file, 1MB)

12 June 2014

Shareholder Update: June 2014

In this issue:

› VivaGel® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel®-coated condom: preparing for launch

› VivaGel® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals

 

Download: Shareholder Update: June 2014 ( pdf file, 2MB)

17 December 2013

Shareholder Update: December 2013

In this issue:

› Dendrimer-Docetaxel to enter human clinical trials

› VivaGel® Phase 3 trial for prevention of recurrent BV

› VivaGel®-coated condom: Consumer feedback

› Impressive results for Dendrimer-Enhanced Oxaliplatin

› Progress continues in agrochemical activities

› Appointment of Rob Thomas

› SPL TV – a new channel

 

Download: Shareholder Update: December 2013 ( pdf file, 1MB)

24 May 2013

Shareholder Update: May 2013

In this issue:

›  VivaGel® update

› New agrochemical partnership

› SPL7013 shows therapeutic potential in viral conjunctivitis

› Positive dendrimer-doxorubicin results

› Key patents obtained

› R&D tax refund received

› Momentum builds in nanomedicine

› Substantial holders increase their stake

Download: Shareholder Update: May 2013 ( pdf file, 1MB)

19 December 2012

Shareholder Update: December 2012

In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

© Starpharma Holdings Limited 2017